Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Retained Earnings (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Retained Earnings for 7 consecutive years, with -$594.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 457253.85% to -$594.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$594.3 million, a 457253.85% decrease, with the full-year FY2025 number at -$594.3 million, down 457253.85% from a year prior.
  • Retained Earnings was -$594.3 million for Q4 2025 at Fulcrum Therapeutics, down from $241000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $241000.0 in Q3 2025 to a low of -$594.3 million in Q4 2025.
  • A 5-year average of -$220.2 million and a median of -$248.5 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 15124900.0% in 2021, then soared 195.59% in 2024.
  • Fulcrum Therapeutics' Retained Earnings stood at -$302.5 million in 2021, then skyrocketed by 99.74% to -$797000.0 in 2022, then soared by 82.94% to -$136000.0 in 2023, then skyrocketed by 195.59% to $130000.0 in 2024, then plummeted by 457253.85% to -$594.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Retained Earnings are -$594.3 million (Q4 2025), $241000.0 (Q3 2025), and $82000.0 (Q2 2025).